Association of @entity6 with use of atypical neuroleptics in the treatment of XXXX .

@entity2175 @entity1 @entity1088 @entity6 @entity161 @entity1037 @entity1089 @entity1090
OBJECTIVE: The development of both type I and @entity2175 after initiation of some atypical neuroleptics has been reported, primarily in studies involving small series of @entity1 . This study used administrative data from a large national sample of @entity1 with a diagnosis of @entity161 to compare the prevalence of @entity6 in @entity1 receiving prescriptions for atypical and typical neuroleptics. METHOD: All outpatients with @entity161 treated with typical and atypical neuroleptics over 4 months in 1999 in the Veterans Health Administration of the Department of Veterans Affairs (VA) were included in this study. @entity1 treated with atypical neuroleptics were those who received prescriptions for @entity1088 , @entity1037 , @entity1090 , or @entity1089 . @entity1 with a diagnosis of @entity6 were also identified by using ICD-9 codes in VA administrative databases. The prevalence of @entity6 across age groups and among @entity1 receiving prescriptions for different atypical neuroleptics was examined with multiple logistic regression. RESULTS: A total of 38,632 @entity1 were included in the study: 15,984 (41.4%) received typical neuroleptics and 22,648 (58.6%) received any atypical neuroleptic (1,207 [5.3%] received @entity1088 ; 10,970 [48.4%], @entity1037 ; 955 [4.2%], @entity1089 ; and 9,903 [43.7%], @entity1090 ; 387 @entity1 received prescriptions for more than one atypical neuroleptic). When the effects of age were controlled, @entity1 who received atypical neuroleptics were 9% more likely to have @entity6 than those who received typical neuroleptics, and the prevalence of @entity6 was significantly increased for @entity1 who received @entity1088 , @entity1037 , and @entity1089 , but not @entity1090 . However, for @entity1 less than 40 years old, all of the atypical neuroleptics were associated with a significantly increased prevalence of @entity6 . CONCLUSIONS: In this large group of @entity1 with @entity161 , receipt of a prescription for atypical neuroleptics was significantly associated with @entity6 .
